Search research articles
Contact Us
Filters
Showing results (141-150 of 152) with videos related to
Page
of 16
Sort By:
British Journal of Haematology
|
December 5, 2023
PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation
Zhixiang Wang, Zhiping Fan, Zhengwei Wu, et al.
The Lancet. Haematology
|
July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
Li Xuan, Yu Wang, Kaibo Yang, et al.
Experimental Hematology & Oncology
|
July 9, 2025
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial
Ke Zhao, Ren Lin, Zhiping Fan, et al.
Journal of Hematology & Oncology
|
April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Hua Jin, Yu Zhang, Sijian Yu, et al.
Blood Cancer Journal
|
December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes
Sijian Yu, Tong Lin, Danian Nie, et al.
British Journal of Haematology
|
May 21, 2025
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study
Yiling Ye, Xinyu Liu, Huajuan Dai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 12, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Guopan Yu, Yu Zhang, Sijian Yu, et al.
JAMA Network Open
|
July 7, 2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Sijian Yu, Zhiping Fan, Liping Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial
Haiyan Zhang, Zhiping Fan, Fen Huang, et al.
Journal of Internal Medicine
|
October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study
Sijian Yu, Yu Zhang, Guopan Yu, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 152) with videos related to
Sort By:
Page
of 16
British Journal of Haematology
|
December 5, 2023
PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation
Zhixiang Wang, Zhiping Fan, Zhengwei Wu, et al.
The Lancet. Haematology
|
July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
Li Xuan, Yu Wang, Kaibo Yang, et al.
Experimental Hematology & Oncology
|
July 9, 2025
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial
Ke Zhao, Ren Lin, Zhiping Fan, et al.
Journal of Hematology & Oncology
|
April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Hua Jin, Yu Zhang, Sijian Yu, et al.
Blood Cancer Journal
|
December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes
Sijian Yu, Tong Lin, Danian Nie, et al.
British Journal of Haematology
|
May 21, 2025
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study
Yiling Ye, Xinyu Liu, Huajuan Dai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 12, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Guopan Yu, Yu Zhang, Sijian Yu, et al.
JAMA Network Open
|
July 7, 2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Sijian Yu, Zhiping Fan, Liping Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial
Haiyan Zhang, Zhiping Fan, Fen Huang, et al.
Journal of Internal Medicine
|
October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study
Sijian Yu, Yu Zhang, Guopan Yu, et al.
Page
of 16